Scribd
Upload
76 views15 pages

Remicade

Uploaded by

Gerald Noah Faustino
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
76 views15 pages

Remicade

Uploaded by

Gerald Noah Faustino
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
You are on page 1/ 15

Infliximab (Remicade)

Remicade
● Active substance: Infliximab
● Developed by Junming Le and Jan Vilcek at the New York School of
Medicine.
Remicade
● Chimeric (human-murine) monoclonal antibody directed against tumor
necrosis factor alpha.
○ Approx. 30% murine variable region - confers antigen-binding specificity to human TNF-alpha
○ 70 % remaining - human IgG1 heavy chain constant region and a human kappa light chain
constant region
Remicade
● Approved on August, 1998 for acute treatment of moderate to severe Crohn’s
disease in patients who have had an inadequate response to conventional
therapy
○ Making Remicade as the first TNF-alpha inhibitor in the US
Biotech
Development genetics

● Infliximab monoclonal antibody is expressed using chimeric antibody genes


consisting of the variable region sequences cloned from the murine anti-TNF
alpha hybridoma A2, and human antibody constant region sequences
supplied by the plasmid expression vectors.
● Generation of murine anti-TNF alpha hybridoma - immunization of BALB/c
mice with purified recombinant human TNF alpha.
Biotech
Manufacture

● Infliximab is a recombinant antibody


● Produced and secreted from mouse myeloma cells (SP2/0 cells)
○ Formed by fusing BALB/c spleen cells (mouse immunized with sheep red blood cells) with the
P3X63Ag8
● The antibody is manufactured by continuous perfusion cell culture.
● Collected harvest are clarified by filtration before further purification.
Indications
Inflammatory diseases such as:
● rheumatoid arthritis
● psoriatic arthritis
● ulcerative colitis
● Crohn's disease
● severe or disabling plaque psoriasis.
Dosage form
● 100 mg of lyophilized infliximab in a 20 mL vial for intravenous infusion.
Mechanism of action
● chimeric monoclonal antibody which binds w/ high affinity to the soluble and
transmembrane forms of tumour necrosis factor-α (TNF-α) thereby inhibiting
binding of TNF-α to its receptors.

*TNFa, a cytokine produced by white blood cells, has an important role in the
body’s protective function, but the overproduction of TNF a leads to inflammation.
Mechanism of Action

Excess amounts of TNF-alpha cause your immune REMICADE® belongs to a class of biologic
system to mistakenly attack healthy cells leading to medications known as TNF-blockers. REMICADE®
inflammation—the underlying cause of Crohn’s binds to TNF-alpha, blocking its actio
symptoms
Adverse Drug Reaction
Patients treated with Remicade are at increased risk for developing serious
infections that may lead to hospitalization or death

● Concomitant immunosuppressants (methotrexate or corticosteroid)

Reported infections:

● Active tuberculosis and reactivation of latent tuberculosis


○ Should be tested and treated prior to initiating Remicade therapy
Adverse Drug Reaction
Other reported infections:

● Invasive fungal infections (histoplasmosis, coccidioidomycosis, candidiasis,


aspergillosis, blastomycosis and pneumocystis)
○ Can develop into serious systemic illness
● Malignancy
○ Lymphoma - Hodgkin and Non-hodgkin lymphoma
● Opportunistic infections
Related Update and Studies
Dosing related studies for the treatment of:

● Rheumatoid arthritis
● Ankylosing spondylitis
● Crohn’s disease
● Ulcerative colitis
● Psoriatic arthritis
● Plaque psoriasis
Related Updates and Studies

You might also like